Vikas Dharnidharka is a Nephrology physician affiliated with Rutgers. OpenAlex indexes 340 publications with 12,493 citations (h-index 55). By OpenAlex citation count, this profile ranks in the top 10% of Pediatric Nephrology profiles in the findmyKOL directory.
Overview
Scholarship
indexed output and impact (OpenAlex)Distinct works indexed by OpenAlex, matched via ORCID.
Total citations across indexed works.
Hirsch index, productivity × impact (OpenAlex).
Clinical & industry
trials, payments and federal fundingContact
The practice address and phone this provider lists in the federal NPPES (CMS) registry.
Practice address
89 French St
New Brunswick, NJ 089011935
Telephone
732-235-7400Provider last certified this registry record 29 Oct 2024.
Industry payments
6 companies reported payments to CMS in program years 2021 onward. These are public disclosures, not judgments. The latest:
- Alnylam Pharmaceuticals Inc.Program year20251 payment
- AstraZeneca Pharmaceuticals LPProgram year20241 payment
- Calliditas Therapeutics US Inc.Program year20231 payment
Payment records matched to this physician's NPI in CMS Open Payments, program years 2021 onward.
Medicare prescribing footprint (2023)
The drugs this prescriber writes for Medicare patients, grouped by drug class and therapeutic area. Every percentage is a share of their total prescribing, so you can see what they prescribe most. These are proportions, not patient counts or dollar amounts. No condition is inferred: the claims record what was prescribed, never why.
Cardiovascular
100%Central alpha-2 Adrenergic Agonist100%Clonidine Hcl100%Part D<11 patients
Drug classes come from the WHO ATC and U.S. National Library of Medicine (RxClass) classifications; prescribing counts come from the CMS Medicare Part D Prescribers file. Each drug is counted once, under its primary class. Medicare fee-for-service only, so no Medicare Advantage, commercial, or pediatric prescribing is included. CMS publishes this data about 17 months after the fact.
NIH funding
3 NIH research awards on record, funded 2024–2026 per NIH RePORTER. The latest:
- Choosing Immune Suppression in Renal Transplantation by Efficacy and Morbidity 2 (CISTEM2)
Rutgers Biomedical and Health Sciences
FY2026$644,764R01DK139339 - Understanding the immune response changes to clinical interventions for Epstein-Barr virus infection prior to lymphoma development in children after organ transplants (UNEARTH)
Rutgers Biomedical and Health Sciences
FY2025$945,993U01CA275304 - Choosing Immune Suppression in Renal Transplantation by Efficacy and Morbidity 2 (CISTEM2)
Rutgers Biomedical and Health Sciences
FY2025$561,098R01DK139339
Awards in the NIH RePORTER records where a principal investigator name matches this physician at an organization in their practice state. Latest award years shown; each row links to the project record on RePORTER.
Similar KOLs
Other experts from the same institution or the same specialty.
Sherine Gabriel, MD
Rutgers
Julius Gardin, MD
Rutgers
Abraham Aviv, MD
Rutgers
Partho Sengupta, MD, DM
Rutgers
A basic profile from our physician directory: identity and practice contact from the federal NPPES registry, research from OpenAlex, trials from ClinicalTrials.gov, payments from CMS Open Payments — shown itemized where we have matched records, as a count where we only have a total. This person hasn't been through our full identity-adjudication pipeline yet, so funding, congress activity and public presence aren't shown. Absence of a section means “not yet looked,” never “none found.”